糖酵解与线粒体功能障碍的关系及其在肝脏疾病中的潜在价值

颜耿杰; 林镛; 苏会吉; 陈含笑; 班少群; 韦艾凌; 毛德文; 龙富立

doi:10.3969/j.issn.1001-5256.2022.08.042

糖酵解与线粒体功能障碍的关系及其在肝脏疾病中的潜在价值

DOI: 10.3969/j.issn.1001-5256.2022.08.042

颜耿杰¹,
林镛¹,
苏会吉¹,
陈含笑¹,
班少群¹,
韦艾凌^{1, 2},
毛德文²,
龙富立^2, , ,

1.
广西中医药大学研究生院，南宁 530200
2.
广西中医药大学第一附属医院肝病二区，南宁 530023

基金项目:

国家自然科学基金 (81960841);

国家科技重大专项 (2018ZX10725505-001-011);

广西科技计划项目 (2020GXNSFAA297098);

广西中医药大学校级硕士研究生创新项目 (YCXJ2021034)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：颜耿杰负责课题设计，资料分析，撰写论文；林镛、苏会吉、陈含笑、班少群参与收集数据，修改论文；毛德文、韦艾凌、龙富立负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
龙富立，longfuli005@163.com

计量
- 文章访问数: 914
- HTML全文浏览量: 673
- PDF下载量: 95
- 被引次数: 0
出版历程
- 收稿日期: 2022-04-18
- 录用日期: 2022-05-29
- 出版日期: 2022-08-20

Association between glycolysis and mitochondrial dysfunction and its potential value in liver diseases

1.
Graduate School of Guangxi University of Chinese Medicine, Nanning 530200, China
2.
Second Ward of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

National Natural Science Foundation of China (81960841);

National Science and Technology Major Project (2018ZX10725505-001-011);

Guangxi Science and Technology Project (2020GXNSFAA297098);

Guangxi University of Traditional Chinese Medicine Graduate Innovation Project (YCXJ2021034)

More Information

Corresponding author: LONG Fuli, longfuli005@163.com(ORCID: 0000-0003-1196-2697)

摘要

摘要: 糖酵解在肝脏疾病的发生发展中发挥着重要作用。在不同肝脏疾病中，糖酵解活性显示出不同程度的增强，并与线粒体功能障碍(氧化磷酸化功能缺陷和活性氧产生)密切相关，这有助于填补由氧化磷酸化受损而导致的能量产生缺陷。因此，或可通过靶向调节有氧糖酵解中的关键因素，例如抑制酶己糖激酶2、M2型丙酮酸激酶或其他调节途径，寻求肝脏疾病的潜在治疗新方法。本文从糖酵解与肝脏疾病的相互关系出发，阐述糖酵解在肝脏疾病中的治疗意义和潜在价值，以期为肝脏疾病治疗提供新思路。
- 肝疾病 /
- 糖酵解 /
- 线粒体
Abstract: Glycolysis plays an important role in the development and progression of liver diseases and shows varying degrees of enhancement in different liver diseases, and it is closely associated with mitochondrial dysfunction (oxidative phosphorylation deficiency and reactive oxygen species production), which helps to fill energy production deficiency caused by impaired oxidative phosphorylation. Therefore, it might be possible to search for potential new therapies for liver diseases through targeted regulation of the key factors in aerobic glycolysis, such as hexokinase 2, pyruvate kinase M2, and other regulatory pathways. From the perspective of the association between glycolysis and liver diseases, this article elaborates on the therapeutic significance and potential value of glycolysis in liver diseases, in order to provide new ideas for the diagnosis and treatment of liver diseases.
- Liver Diseases /
- Glycolysis /
- Mitochondria

HTML全文

图 1 有氧糖酵解的过程及其3种限速酶

注：HK2、PFK1和PKM2是糖酵解过程中的3种限速酶。HK2可催化葡萄糖生成6-磷酸葡萄糖，并与线粒体外膜上的VDAC1相互作用和结合，从而促进ATP的产生和抑制细胞凋亡。PFK1可催化F-6-P为FDP，其活性受PFKFB3催化产物F-2, 6-BP的调节。PKM2不仅能够催化PEP合成丙酮酸，还能够移位至细胞核内，与一些转录因子如HIF-1α、β-catenin/c-Myc、NF-κB和STAT3共同激活，促进相关靶基因的转录。

Figure 1. The process of glycolysis and its three rate limiting enzymes

下载: 全尺寸图片幻灯片

参考文献(45)

[1]	AUGER C, ALHASAWI A, CONTAVADOO M, et al. Dysfunctional mitochondrial bioenergetics and the pathogenesis of hepatic disorders[J]. Front Cell Dev Biol, 2015, 3: 40. DOI: 10.3389/fcell.2015.00040.
[2]	WALLACE DC, FAN W, PROCACCIO V. Mitochondrial energetics and therapeutics[J]. Annu Rev Pathol, 2010, 5: 297-348. DOI: 10.1146/annurev.pathol.4.110807.092314.
[3]	NISHIKAWA T, BELLANCE N, DAMM A, et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease[J]. J Hepatol, 2014, 60(6): 1203-1211. DOI: 10.1016/j.jhep.2014.02.014.
[4]	GO Y, JEONG JY, JEOUNG NH, et al. Inhibition of pyruvate dehydrogenase kinase 2 protects against hepatic steatosis through modulation of tricarboxylic acid cycle anaplerosis and ketogenesis[J]. Diabetes, 2016, 65(10): 2876-2887. DOI: 10.2337/db16-0223.
[5]	ZHANG M, ZHAO Y, LI Z, et al. Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis[J]. Biochem Biophys Res Commun, 2018, 495(1): 582-586. DOI: 10.1016/j.bbrc.2017.11.054.
[6]	SHIRAI T, NAZAREWICZ RR, WALLIS BB, et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease[J]. J Exp Med, 2016, 213(3): 337-354. DOI: 10.1084/jem.20150900.
[7]	MIDDLETON P, VERGIS N. Mitochondrial dysfunction and liver disease: role, relevance, and potential for therapeutic modulation[J]. Therap Adv Gastroenterol, 2021, 14: 17562848211031394. DOI: 10.1177/17562848211031394.
[8]	GABBIA D, CANNELLA L, DE MARTIN S. The role of oxidative stress in NAFLD-NASH-HCC transition-focus on NADPH oxidases[J]. Biomedicines, 2021, 9(6): 687. DOI: 10.3390/biomedicines9060687.
[9]	LEE N, CARELLA MA, PAPA S, et al. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer[J]. Front Cell Dev Biol, 2018, 6: 138. DOI: 10.3389/fcell.2018.00138.
[10]	LI S, LI J, DAI W, et al. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death[J]. Br J Cancer, 2017, 117(10): 1518-1528. DOI: 10.1038/bjc.2017.323.
[11]	YE JH, CHAO J, CHANG ML, et al. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation[J]. Sci Rep, 2016, 6: 33102. DOI: 10.1038/srep33102.
[12]	SHANG RZ, QU SB, WANG DS. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects[J]. World J Gastroenterol, 2016, 22(45): 9933-9943. DOI: 10.3748/wjg.v22.i45.9933.
[13]	LUNT SY, VANDER HEIDEN MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation[J]. Annu Rev Cell Dev Biol, 2011, 27: 441-464. DOI: 10.1146/annurev-cellbio-092910-154237.
[14]	SCIACOVELLI M, GAUDE E, HILVO M, et al. The metabolic alterations of cancer cells[J]. Methods Enzymol, 2014, 542: 1-23. DOI: 10.1016/B978-0-12-416618-9.00001-7.
[15]	LIU J, JIANG S, ZHAO Y, et al. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions[J]. J Pathol, 2018, 246(3): 277-288. DOI: 10.1002/path.5131.
[16]	KORS L, RAMPANELLI E, STOKMAN G, et al. Deletion of NLRX1 increases fatty acid metabolism and prevents diet-induced hepatic steatosis and metabolic syndrome[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5 Pt A): 1883-1895. DOI: 10.1016/j.bbadis.2018.03.003.
[17]	SHANNON CE, RAGAVAN M, PALAVICINI JP, et al. Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease[J]. Mol Metab, 2021, 45: 101154. DOI: 10.1016/j.molmet.2020.101154.
[18]	WANG T, CHEN K, YAO W, et al. Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance[J]. J Hepatol, 2021, 74(5): 1038-1052. DOI: 10.1016/j.jhep.2020.11.028.
[19]	SHIMADA K, CROTHER TR, KARLIN J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis[J]. Immunity, 2012, 36(3): 401-414. DOI: 10.1016/j.immuni.2012.01.009.
[20]	XU F, GUO M, HUANG W, et al. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH[J]. Redox Biol, 2020, 36: 101634. DOI: 10.1016/j.redox.2020.101634.
[21]	SUN M, KISSELEVA T. Reversibility of liver fibrosis[J]. Clin Res Hepatol Gastroenterol, 2015, 39(Suppl 1): S60-S63. DOI: 10.1016/j.clinre.2015.06.015.
[22]	WANG F, JIA Y, LI M, et al. Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells[J]. Cell Commun Signal, 2019, 17(1): 11. DOI: 10.1186/s12964-019-0324-8.
[23]	WAN L, XIA T, DU Y, et al. Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2: a role for exosomes in metabolic switch of liver nonparenchymal cells[J]. FASEB J, 2019, 33(7): 8530-8542. DOI: 10.1096/fj.201802675R.
[24]	HUANG T, LI YQ, ZHOU MY, et al. Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway[J]. World J Gastroenterol, 2022, 28(1): 123-139. DOI: 10.3748/wjg.v28.i1.123.
[25]	RAO J, WANG H, NI M, et al. FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2[J]. Gut, 2022. DOI: 10.1136/gutjnl-2021-325150.[Online ahead of print]
[26]	ZHENG D, JIANG Y, QU C, et al. Pyruvate kinase M2 tetramerization protects against hepatic stellate cell activation and liver fibrosis[J]. Am J Pathol, 2020, 190(11): 2267-2281. DOI: 10.1016/j.ajpath.2020.08.002.
[27]	ZHOU MY, CHENG ML, HUANG T, et al. Transforming growth factor beta-1 upregulates glucose transporter 1 and glycolysis through canonical and noncanonical pathways in hepatic stellate cells[J]. World J Gastroenterol, 2021, 27(40): 6908-6926. DOI: 10.3748/wjg.v27.i40.6908.
[28]	BAN D, HUA S, ZHANG W, et al. Costunolide reduces glycolysis-associated activation of hepatic stellate cells via inhibition of hexokinase-2[J]. Cell Mol Biol Lett, 2019, 24: 52. DOI: 10.1186/s11658-019-0179-4.
[29]	MATHUPALA SP, KO YH, PEDERSEN PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy[J]. Semin Cancer Biol, 2009, 19(1): 17-24. DOI: 10.1016/j.semcancer.2008.11.006.
[30]	VAUPEL P, SCHMIDBERGER H, MAYER A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression[J]. Int J Radiat Biol, 2019, 95(7): 912-919. DOI: 10.1080/09553002.2019.1589653.
[31]	DEWAAL D, NOGUEIRA V, TERRY AR, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J]. Nat Commun, 2018, 9(1): 446. DOI: 10.1038/s41467-017-02733-4.
[32]	MATHUPALA SP, KO YH, PEDERSEN PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy[J]. Semin Cancer Biol, 2009, 19(1): 17-24. DOI: 10.1016/j.semcancer.2008.11.006.
[33]	KANAI S, SHIMADA T, NARITA T, et al. Phosphofructokinase-1 subunit composition and activity in the skeletal muscle, liver, and brain of dogs[J]. J Vet Med Sci, 2019, 81(5): 712-716. DOI: 10.1292/jvms.19-0049.
[34]	BARTRONS R, RODRÍGUEZ-GARCÍA A, SIMON-MOLAS H, et al. The potential utility of PFKFB3 as a therapeutic target[J]. Expert Opin Ther Targets, 2018, 22(8): 659-674. DOI: 10.1080/14728222.2018.1498082.
[35]	LI S, DAI W, MO W, et al. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma[J]. Int J Cancer, 2017, 141(12): 2571-2584. DOI: 10.1002/ijc.31022.
[36]	van NIEKERK G, ENGELBRECHT AM. Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target[J]. Cell Oncol (Dordr), 2018, 41(4): 343-351. DOI: 10.1007/s13402-018-0383-7.
[37]	AZOITEI N, BECHER A, STEINESTEL K, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation[J]. Mol Cancer, 2016, 15: 3. DOI: 10.1186/s12943-015-0490-2.
[38]	LUO W, HU H, CHANG R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J]. Cell, 2011, 145(5): 732-744. DOI: 10.1016/j.cell.2011.03.054.
[39]	WONG N, OJO D, YAN J, et al. PKM2 contributes to cancer metabolism[J]. Cancer Lett, 2015, 356(2 Pt A): 184-191. DOI: 10.1016/j.canlet.2014.01.031.
[40]	FENG J, WU L, JI J, et al. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 204. DOI: 10.1186/s13046-019-1194-z.
[41]	LIU B, JIN J, ZHANG Z, et al. Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway[J]. Biochem Cell Biol, 2019, 97(4): 397-405. DOI: 10.1139/bcb-2018-0310.
[42]	LING Y, YAN GJ, FENG F, et al. Association between cholesterol and liver regeneration and its significance and potential value in clinical treatment of liver failure[J]. J Clin Hepatol, 2022, 38(3): 708-713. DOI: 10.3969/j.issn.1001-5256.2022.03.044. 林镛, 颜耿杰, 冯逢, 等. 胆固醇与肝再生关系及其在肝衰竭治疗中的意义和潜在价值[J]. 临床肝胆病杂志, 2022, 38(3): 708-713. DOI: 10.3969/j.issn.1001-5256.2022.03.044.
[43]	WANG Y, LI X, CHEN Q, et al. Histone deacetylase 6 regulates the activation of M1 macrophages by the glycolytic pathway during acute liver failure[J]. J Inflamm Res, 2021, 14: 1473-1485. DOI: 10.2147/JIR.S302391.
[44]	WANG XF, SHI QL, WANG MG, et al. Experimental study on effect of Jiedu Huayu granules on hepatic mitochondrial permeability transition in rats with acute liver failure[J]. Liaoning J Tradit Chin Med, 2017, 44(10): 2186-2189. DOI: 10.13192/j.issn.1000-1719.2017.10.056. 王秀峰, 石清兰, 王明刚, 等. 解毒化瘀颗粒抑制急性肝衰竭大鼠肝线粒体通透性转换的实验研究[J]. 辽宁中医杂志, 2017, 44(10): 2186-2189. DOI: 10.13192/j.issn.1000-1719.2017.10.056.
[45]	ZHANG RZ, MAO DW, SUN KW, et al. Mechanism of action of Jieduhuayu granules for remission of oxidative stress in hepatocytes[J]. Chin J Hepatol, 2021, 29(12): 1188-1193. DOI: 10.3760/cma.j.cn501113-20210721-00349. 张荣臻, 毛德文, 孙克伟, 等. 解毒化瘀颗粒缓解肝细胞氧化应激的作用机制[J]. 中华肝脏病杂志, 2021, 29(12): 1188-1193. DOI: 10.3760/cma.j.cn501113-20210721-00349.